Introduction {#s1}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is widespread in hospital and community settings and has become progressively costly to treat and control [@pone.0079149-Lee1]--[@pone.0079149-Kim1]. In Alberta, Canada, MRSA was designated as a "pathogen under surveillance" since June 2005 by Alberta Health, requesting all regional laboratories to submit the first clinical MRSA isolate from each patient within a one year period to the Provincial Laboratory for Public Health (ProvLab) for molecular typing. Routine MRSA genotyping identifies trends in prevalence, distribution, and epidemiology in an effort to enhance patient outcome and reduce transmission. Global dissemination of MRSA is largely attributed to a small number of epidemic MRSA clones that are often predominant in specific geographic regions [@pone.0079149-Grundmann1]--[@pone.0079149-Oliveira1]. Ten Canadian pulsed-field gel electrophoresis (PFGE) epidemic types (CMRSA 1 to CMRSA 10) have been identified using PFGE by the Canadian Nosocomial Infection Surveillance Program [@pone.0079149-Christianson1], [@pone.0079149-Simor1].

Although PFGE characterization is useful, it is a labor-intensive and time-consuming technique. Furthermore, PFGE results are prone to subjective interpretation making inter-laboratory comparisons difficult [@pone.0079149-Trindade1]. The number of MRSA isolates submitted annually to ProvLab for genotyping has increased dramatically from 1999 to 2008: with an average of 93 isolates per year in 1999--2004, to an average of 3106 isolates per year in 2005--2008. The difficulties associated with PFGE are enhanced with this increase, making an alternative typing method necessary.

*Staphylococcus* protein A (*spa*) typing is a DNA sequencing assay that assigns *spa* types based on the repeats present in the polymorphic X region of the *Staphylococcus* protein A gene [@pone.0079149-Shopsin1]. The National Microbiology Laboratory (NML) in Winnipeg, Canada, uses *spa* typing for MRSA characterization because of the high concordance observed between *spa* types and PFGE epidemic types [@pone.0079149-Golding1]--[@pone.0079149-Koreen1]. However, some *spa* types correspond to multiple PFGE epidemic types and require additional molecular typing before they can be grouped into a PFGE epidemic type [@pone.0079149-Golding1]. Golding *et al*., [@pone.0079149-Golding1] propose that a PCR-based assay to detect the presence of Panton-Valentine leukocidin (PVL) [@pone.0079149-Lina1] helps to differentiate these strains. Staphylococcal cassette chromosome (SCC*mec*) typing targeting the *mec* gene complex could also further assist differentiation [@pone.0079149-Oliveira2], [@pone.0079149-Kondo1].

In this study, we describe the transition from PFGE-based assignment of Canadian PFGE epidemic types to using *spa*, SCC*mec*, and PVL typing. The cost, turn-around times, and assigned PFGE epidemic types using the two different methodologies are compared. This study also evaluates whether SCC*mec* and PVL data can differentiate MRSA isolates that share the same *spa* type but are associated with multiple PFGE epidemic types.

Materials and Methods {#s2}
=====================

Bacterial Strains and DNA Extraction {#s2a}
------------------------------------

There were three sets of MRSA isolates characterized in this study. The first set includes a selection of 1269 isolates from samples submitted to ProvLab for routine molecular typing between June 2005 and March 2009. These isolates were previously genotyped using PFGE, SCC*mec*, and PVL typing and were selected because they had a unique combination of PFGE, SCC*mec*, and PVL types. The 1269 isolates comprised the validation panel and were *spa* typed and used to populate the Alberta MRSA *spa* typing database. The second set consists of an additional 646 consecutive post-validation clinical isolates received by ProvLab between August 2009 and November 2009. These isolates were *spa*, SCC*mec*, and PVL typed and used for the preliminary evaluation of the developed MRSA typing algorithm. Lastly, ongoing routine MRSA molecular typing continued from January 2010 to December 2012 and included 12620 isolates that were used to determine the efficacy of the typing method as well as the associated time and cost requirements. MRSA isolates were inoculated onto sheep blood agar plates (BAPs; Dalynn Biologicals, Calgary, Alberta, Canada) from frozen cultures for overnight growth at 37°C. DNA was extracted using a modified method described by Holland *et al*. [@pone.0079149-Holland1]. A single colony was picked from the BAP and suspended in 200 µL of rapid lysis buffer (100 mM NaCl, 10 mM Tris-HCl pH 8.3, 1 mM EDTA pH 9.0, 1% Triton-X), kept frozen at −80°C for 15 minutes, and boiled for 15 minutes. Following cooling at room temperature and centrifugation at 13,000×*g* for five minutes, supernatant was removed and used as DNA template for PCR.

*spa* Typing {#s2b}
------------

PCR was performed using primers targeting the *spa* gene as described by Golding *et al.* [@pone.0079149-Golding1]. PCR products from isolates in the validation panel (n = 1269) and post-validation isolates (n = 646) were sent to the Genomic Core DNA facility at the National Microbiology Laboratory (NML) in Winnipeg, Canada, for PCR product cleanup and sequencing. PCR products of isolates that were part of ongoing routine molecular typing (n = 12620) were cleaned and sequenced at ProvLab.

PFGE, SCC*mec*, and PVL Typing {#s2c}
------------------------------

PFGE was performed as previously described by Mulvey *et al*. [@pone.0079149-Mulvey1] using the restriction endonuclease *Sma*I. PFGE results were analyzed using BioNumerics (version 5.1; Applied Maths, USA) and PFGE epidemic type designation was completed based on guidelines detailed by NML and using PFGE fingerprint profiles of reference strains provided by NML [@pone.0079149-Christianson1], [@pone.0079149-Simor1]. Briefly, isolates were assigned to a PFGE epidemic type if there was a difference of less than seven bands between the PFGE fingerprint pattern of the isolate and a provided reference strain. Isolates were designated as "non-assigned" if they differed by more than seven bands from all reference strains. All isolates were grouped into one of the following PFGE epidemic types: Canadian community-associated MRSA (CA-MRSA) epidemic clones CMRSA 2 (USA800; ST5), CMRSA 7 (USA400; ST1), and CMRSA 10 (USA300; ST8); Canadian hospital-associated MRSA (HA-MRSA) epidemic clones CMRSA 1 (USA600; ST45), CMRSA 2 (USA100, ST5), CMRSA 3/6 ("Punjabi" clone; ST239), CMRSA 4 (USA200; ST36), CMRSA 5 (USA500; ST8), CMRSA 8 (EMRSA-15; ST-22), and CMRSA 9 (no USA equivalent); European epidemic clones (ST88, ST97, and ST80); epidemic clones from the United States USA700 (ST72), USA1000 (China/Taiwan; ST59), and USA1100 (Southwest Pacific(SWP)/Oceania; ST30). SCC*mec* typing was performed using the primers and methods described by Oliveira *et al*. [@pone.0079149-Oliveira2]. Epidemic types USA100 and USA800, both characterized as Canadian epidemic type CMRSA 2, were differentiated using SCC*mec* data as only USA800 is SCC*mec* type IV [@pone.0079149-Golding1], [@pone.0079149-McDougal1]. Isolates that could not be typed using the Oliveria *et al.* protocol [@pone.0079149-Oliveira2] were SCC*mec* typed using the method outlined in Kondo *et al*. [@pone.0079149-Kondo1]. There were no isolates in this study that were not typeable by both methods. PVL characterization [@pone.0079149-Lina1] was performed using previously described methods.

Data Analysis {#s2d}
-------------

Sequencing results for validation and post-validation isolates were obtained from the Genomic Core DNA facility website; sequencing results for isolates part of ongoing routine molecular typing at ProvLab between January 2010 and December 2012 were obtained in-house. All sequences were analyzed in BioNumerics, and submitted to the online Ridom *spa* server (<http://www.ridom.de/spaserver>), developed by Ridom GmbH and curated by SeqNet.org (<http://www.SeqNet.org>), for Ridom *spa* type designation [@pone.0079149-Harmsen1]. For the validation isolates (n = 1269) that were genotyped using PFGE, SCC*mec*, and PVL typing prior to this study, *spa*-based assignment of PFGE epidemic types was done using databases from NML [@pone.0079149-Golding1] and Sunnybrook Health Sciences Centre (unpublished data) in Toronto, Canada, that correlate *spa* types with PFGE epidemic types. PFGE epidemic type designations based on *spa* data and PFGE data were compared. Post-validation (n = 646) and ongoing routine molecular typing (n = 12620) isolates were assigned PFGE epidemic types using the Alberta MRSA *spa* typing database and the typing algorithm outlined in this study. Simpson's Index of Diversity [@pone.0079149-Simpson1] was calculated using the online tool hosted at the Comparing Partitions website (<http://darwin.phyloviz.net/ComparingPartitions/>).

Alberta MRSA Typing Database {#s2e}
----------------------------

The genotyping results and PFGE epidemic type designations from the isolates in the validation panel (n = 1269) were used as the initial dataset to build the Alberta MRSA typing database. An algorithm to assign PFGE epidemic types based on the association between *spa*, SCC*mec*, and PVL types with PFGE epidemic types was developed. The database and the algorithm were evaluated using the post-validation subset of isolates (n = 646). PFGE was then performed on a random selection of the post-validation samples to determine if there is a consensus in PFGE epidemic type designation between the different typing methods. Genotyping data from the post-validation isolates and the isolates that were part of routine testing at ProvLab was added to the Alberta MRSA typing database.

Cost and Time Analysis {#s2f}
----------------------

The cost and time analysis was based on routine testing of 12620 MRSA isolates submitted to ProvLab for genotyping between January 2010 and December 2012. Values were calculated by averaging the time required for genotyping batches of 20 MRSA isolates during the study period and were rounded to the nearest half hour. Turn-around time calculations began from the isolation of single colonies from overnight cultures and ended when data analysis was complete. Hands-on time was expressed as the sum of the average labor and analysis times required from laboratory technologists.

Results {#s3}
=======

Building the Alberta MRSA Typing Database {#s3a}
-----------------------------------------

The association of *spa*, SCC*mec*, and PVL types with PFGE epidemic types for the validation panel of isolates (n = 1269) that were *spa* typed is shown in [Table 1](#pone-0079149-t001){ref-type="table"}. This genotyping data was used as the foundation for the Alberta MRSA typing database. A total of 160 *spa* types were identified and four of these *spa* types- t008, t044, t1081, and t451 (n = 255; 20% of the genotyped isolates) - corresponded to more than one epidemic type. SCC*mec* typing was needed to assign PFGE epidemic types to t008 (n = 228), which is one of the most common *spa* types observed, because of its association with PFGE epidemic types CMRSA5, CMRSA9, and CMRSA10. The majority of the t008 isolates (n = 226; 99.1%) were characterized as SCC*mec* type IV using primers from Oliveira *et al*., [@pone.0079149-Oliveira2] and classified as CMRSA 10. A small number (n = 2) of t008 isolates were not typeable using these primers and could only be SCC*mec* typed using primers from Kondo *et al*. [@pone.0079149-Kondo1]. Both t008 isolates were SCC*mec* type IV and PVL positive and PFGE data was needed to resolve the PFGE epidemic types (one was CMRSA 5; the other was CMRSA 10). PFGE epidemic type classification for *spa* types t044 (n = 17), t1081 (n = 8), and t451 (n = 2) also required PFGE. In total, only 29 of 1269 isolates (2.3%) needed PFGE data for PFGE epidemic type assignment.

10.1371/journal.pone.0079149.t001

###### Association of MRSA PFGE epidemic types with *spa*, SCC*mec*, and PVL types in Alberta from June 2005 to March 2009.

![](pone.0079149.t001){#pone-0079149-t001-1}

  PFGE epidemic type             Ridom *spa* type   Kreiswirth repeat succession   SCC*mec*   PVL   Total
  ----------------------------- ------------------ ------------------------------ ---------- ----- -------
  CMRSA 1 (USA600)                     t004                  A2AKEEMBKB               II       −      2
                                       t026                     XKB                   IV       −      2
                                       t065                  A2AKBEMBKB               IV       −      9
                                                                                     V\*       −      3
                                                                                     VI\*      −      1
                                      t1081                   XKAX2BMB                IV       −      1
                                                                                     V\*       −      1
                                      t1082                   XKBKAMK                 II       −      1
                                       t116                  XKAKEEMBKB               IV       −      2
                                      t1248                  A2AKBEMBKE               IV       −      1
                                                                                     V\*       −      2
                                       t130                   A2BEMBKB                IV       −      1
                                      t1768                  XKAX2BMBMB               IV       −      1
                                       t230                    XKAKB                  II       −      1
                                       t371                   A2AKBKB                 II       −      1
                                                                                      IV       −      1
                                      t5497                     A2AK                 III       −      1
                                      t5980                A2AKBBMBBMBBB              IV       −      1
                                       t715                   A2AKBEMB                IV       −      1
                                       t779                      X                    IV       −      1
                                       t865                   UJGFMBBB                IV      \+      1
                                       t880                    A2AKBB                 IV       −      1
  CMRSA 1 (USA600) Total                                                                             36
  CMRSA 2 (USA100)                     t002                  TJMBMDMGMK               II       −     281
                                       t003                   TMDMGMMK                II       −     88
                                       t010                  TMBMDMGMK                II       −      1
                                       t014                  TMDMGMMMK                II       −     10
                                       t045                   TMDMGMK                 II       −     15
                                       t062                    TJMGMK                 II       −      2
                                       t105                  TJMBMDMMK                II       −      1
                                       t111                     TJMK                  II       −      1
                                      t1154                    TDMGMK                V\*       −      7
                                      t1220                 TJMEMDMGMMK               II       −      1
                                      t1282                  TMDMGMMMMK               II       −      2
                                       t179                  TJMBMDMGGK               II       −      1
                                      t2051                  TJMBMDKGMK               II       −      1
                                       t242                  TJMEMDMGMK               II       −     43
                                      t2958                  C3MBMDMGK               V\*       −      2
                                       t306                 TJMBMDMGMMK               II       −      7
                                       t311                  TJMBDMGMK                II       −      7
                                                                                     V\*       −      3
                                      t3234                    TJMBME                 II       −      1
                                      t3786                   TMDMBMK                 II       −      1
                                      t3948                    TGMMK                  II       −      1
                                       t442                  C3MBMDMGMK              V\*       −      2
                                      t4695                   TJMEMGMK                II       −      1
                                      t5081                   TJMBGMK                V\*       −      1
                                       t548                  TJMBMDMGK                II       −      2
                                       t579                  TJMMDMGMK                II       −      1
                                      t5810                 TMDMGMDMGMMK              II       −      1
                                       t586                      TK                   II       −      1
                                       t688                    TJMBMK                 II       −      2
                                                                                     V\*       −      2
                                       t985                  TJMBMEMGMK               II       −      1
  CMRSA 2 (USA100) Total                                                                             490
  CMRSA 2 (USA800)                     t001                 TO2MBMDMGMK               IV       −      1
                                       t002                  TJMBMDMGMK               IV       −     14
                                                                                              \+     16
                                       t003                   TMDMGMMK                IV      \+      4
                                       t088                 TJMBMDMGGMK               IV       −      3
                                      t1154                    TDMGMK                 IV       −     42
                                      t1781                     TKK                   IV       −      2
                                       t179                  TJMBMDMGGK               IV       −      2
                                       t242                  TJMEMDMGMK               IV       −      1
                                       t306                 TJMBMDMGMMK               IV      \+      1
                                       t311                  TJMBDMGMK                IV       −     33
                                      t5081                   TJMBGMK                 IV       −      3
                                       t539                   TJMBMGMK                IV       −      1
                                       t548                  TJMBMDMGK                IV       −      3
                                                                                              \+      1
                                      t5975                      T?                   IV       −      1
                                      t5987                  TJMBDJMGMK               IV       −      1
                                       t688                    TJMBMK                 IV       −      5
  CMRSA 2 (USA800) Total                                                                             134
  CMRSA 3/6                            t037                   WGKAOMQ                III       −     60
                                       t275                   WGKAOMQQ               III       −      1
  CMRSA 3/6 Total                                                                                    61
  CMRSA 4 (USA200)                     t007                  WGKKKKAOM                II       −      1
                                       t012                  WGKAKAOMQQ               II       −      4
                                                                                      IV       −      3
                                       t018                 WGKAKAOMQQQ               II       −      3
                                       t021                  WGKAKAOMQ                IV       −      2
                                                                                     V\*      \+      1
                                       t233                      WG                   IV       −      1
                                       t318                  WGKKAKAOMQ               IV      \+      1
                                                                                     V\*      \+      1
                                       t338                   WFKAOMQ                 IV       −      1
                                      t3732                   WFKAOMQQ                IV       −      1
                                      t5976                 WGKAAKAOMQQ               IV       −      1
  CMRSA 4 (USA200) Total                                                                             20
  CMRSA 5 (USA500)                     t008                  YHGFMBQBLO              IV\*     \+      1
                                       t064                  YHGCMBQBLO               II       −      1
                                                                                      IV       −      1
                                      t1677                  YHGGMBQBLO               IV       −      1
                                       t451                  YGCMBQBLO                IV       −      1
  CMRSA 5 (USA500) Total                                                                              5
  CMRSA 7 (USA400)                     t127                   UJFKBPE                 II       −      1
                                                                                      IV       −      5
                                       t128                   UJJFKBPE                II       −      3
                                                                                      IV       −     20
                                                                                              \+     19
                                      t1508                    WKBPE                  IV       −      1
                                       t175                  UJFKKPFKPE               IV       −      2
                                                                                              \+      1
                                      t1784                     UBPE                  IV      \+      1
                                      t5469                    UJKPE                  IV       −      1
                                      t5475                    UMBBPB                 II       −      1
                                      t5977                     UJK                   IV      \+      1
                                      t5978                  UJJDFKBPE                IV       −      1
                                      t5979                  UJFFKPFKPE               IV      \+      1
  CMRSA 7 (USA400) Total                                                                             58
  CMRSA 8 (EMRSA-15)                   t005                 TJEJNCMOMOKR             V\*      \+      1
                                       t022              TJEJNF2MNF2MOMOKR            IV       −      5
                                       t032              TJJEJNF2MNF2MOMOKR           IV       −     11
                                                                                              \+      1
                                      t2113              TJJEJNF2MNF2MQOKR            IV       −      1
                                       t223                 TJEJCMOMOKR               IV       −      1
                                                                                     V\*       −      1
                                       t515              TJJEJNF2MNF2MOKKR            IV       −      1
                                       t578              TJJEJNF2MNF2MOMOR            IV       −      4
                                      t5982                UJEJNCMOMOKKR              IV      \+      2
                                      t5983                 UJENCMOMOKR               IV      \+      1
                                       t852                 UJEJNCMOMOKR              IV      \+      3
  CMRSA 8 (EMRSA-15) Total                                                                           31
  CMRSA 10 (USA300)                    t008                  YHGFMBQBLO               IV       −     20
                                                                                              \+     206
                                                                                     IV\*     \+      1
                                       t024                  YGFMBQBLO                IV       −      1
                                                                                      IV      \+      3
                                       t059                     YHO                   IV      \+      1
                                       t121                  YHFMBQBLO                IV      \+      1
                                      t1578                  YHGFMBQBM                IV      \+      1
                                      t1635                   YHGFMBO                 IV      \+      3
                                       t197                   YC2BQBLO                IV      \+      1
                                       t211                 YHGGFMBQBLO               IV      \+      1
                                      t2792                 YHGFMBQBLLO               IV       −      2
                                       t451                  YGCMBQBLO                IV       −      1
                                       t530                  YHGFMBQBK                IV      \+      1
                                      t5989                  YHQFMBQBLO               IV      \+      1
                                       t622                   YHGFMBLO                IV      \+      1
                                       t818                    YHGFMB                 IV       −      1
                                                                                              \+      2
                                       t919                  YHGFKBQBLO               IV       −      1
  CMRSA 10 (USA300) Total                                                                            249
  European                             t044                   UJGBBPB                 IV      \+     14
                                      t5984                    UJGBBB                 IV      \+      1
                                      t5986                   UJGB?PB                 IV      \+      1
  European Total                                                                                     16
  Non-assigned                         t041               TO2MBMDMBMDMGMK             IV       −      1
                                       t078                  ZFGU2DMGGM               IV      \+      1
                                                                                     V\*       −      1
                                       t084                 UJGBBGGJAGJ               II       −      1
                                                                                     III       −      1
                                                                                      IV      \+      1
                                       t091                  UJFMBGJAGJ               IV      \+      1
                                      t1081                   XKAX2BMB                IV       −      2
                                                                                     V\*       −      3
                                                                                              \+      1
                                      t1379                  ZFGMDMGMK                IV       −      1
                                       t149                TO2MEMDMGMGMK              IV       −      2
                                       t160                   UJFQPLM                 II       −      1
                                                                                      IV       −      1
                                                                                              \+      1
                                       t164                  UG2MFBBLB                IV      \+      1
                                      t1839                  TJEFMBBBPB              V\*      \+      1
                                       t202                   YMJMMKKO                IV      \+      2
                                       t209                    UKGJB                  II       −      1
                                       t293                 XKAOP2P2P2P2              IV       −      1
                                      t2982                     XMQ                   IV      \+      1
                                      t3320                 TJEFMBBBQPB              V\*      \+      2
                                       t334                   YGFMBLO                V\*      \+      1
                                       t345                  TJEFMBBPB               V\*      \+      1
                                       t375                  Y2EJCMBPB                II       −      1
                                       t380                     TBPB                  IV       −      1
                                       t405                    UBKBPE                 II       −      1
                                       t455                   UJGBEPB                 IV      \+      1
                                       t525                  Y2BJCMBPB                IV       −      1
                                      t5974                   UBEBBBPB                IV      \+      1
                                      t5981                 TJBFMBBBQPB              V\*      \+      1
                                       t657                   TJEFMBPB               V\*      \+      2
  Non-assigned Total                                                                                 40
  ST88                                t1816                 UGFMBEBBBPB               IV       −      1
                                       t186                  UGFMEEBBPB               IV       −      2
                                      t6441               UEGFMEBW2EBBBPB             IV       −      1
                                       t690                 UGFMEEBBBPB               IV      \+      1
                                       t692                  UGFMBBBBPB               IV      \+      3
  ST88 Total                                                                                          8
  ST97                                 t044                   UJGBBPB                 II       −      1
                                                                                      IV       −      1
                                                                                     V\*       −      1
                                       t131                    UJGBPB                 II       −      1
                                      t2112                 TJGFMBBBBPB               II       −      2
                                                                                     V\*       −      1
                                      t2297                 UJGGFMBBBPB              V\*       −      1
                                       t267                  UJGFMBBBPB               IV       −      4
                                                                                              \+      1
                                       t359                  UJGFMBBPB                IV       −      1
                                       t521                 UJGFMBBBBPB               II       −     18
                                                                                      IV       −      4
                                       t527                 UJGFMBBBBBPB              II       −      2
                                                                                      IV       −      1
  ST97 Total                                                                                         39
  USA1000, China/Taiwan                t163                  ZDMDMA3KB                II       −      1
                                                                                      IV       −      8
                                      t1751                   ZDMDMOE                 IV       −      1
                                       t216                   ZDMDMNKB                IV       −     10
                                                                                              \+      2
                                                                                     V\*       −      2
                                      t2365                     ZDKB                  IV       −      1
                                       t316                    ZDMNKB                 IV       −      1
                                      t3485                  ZDMDMDMOB                IV      \+      3
                                       t437                   ZDMDMOB                 IV       −      1
                                                                                              \+      2
                                                                                     V\*      \+      7
                                       t441                    ZDMOB                  IV       −      1
                                      t4784                  ZDDMDMA3KB              V\*       −      1
                                       t976                   ZDMDNKB                 IV       −      2
  USA1000, China/Taiwan Total                                                                        43
  USA1100, SWP/Oceania                 t019                   XKAKAOMQ                IV      \+     13
                                      t1133                  XKAKAOAOMQ               IV      \+      1
                                      t4341                    XKAMQ                  IV      \+      1
                                      t5447                   UAKAOMQ                 IV      \+      1
  USA1100, SWP/Oceania Total                                                                         16
  USA700                               t126                   UJGFMGGM                IV       −      1
                                      t1346                 UJGFGMDMGGGM              IV       −      4
                                                                                              \+      1
                                       t148                 UJGFGMDMGGM               II       −      1
                                                                                      IV       −      9
                                       t324                  UJGGMDMGGM               IV       −      2
                                      t4359                    UJGGM                 V\*       −      1
                                       t537                  UJGFGDMGG               V\*       −      1
                                       t791                 UJGFGMDMGMM               IV      \+      3
  USA700 Total                                                                                       23
  Grand Total                                                                                       1269

Isolates marked with an \* were SCC*mec* typed using primers from Kondo *et al.* (18); all other isolates were SCC*mec* typed using primers from Oliveira *et al*. (17).

PFGE Epidemic Type Assignment using *spa*, SCC*mec*, and PVL Data {#s3b}
-----------------------------------------------------------------

An algorithm for PFGE epidemic type designation was developed ([Figure 1](#pone-0079149-g001){ref-type="fig"}) based on the data generated for the new Alberta MRSA typing database. Uncharacterized MRSA isolates are *spa*, SCC*mec*, and PVL typed. The typing data is then compared to combinations in the new Alberta MRSA typing database: if a match is found and present in sufficient numbers (at ProvLab the arbitrary minimum count is ten isolates) then the PFGE epidemic type is assigned and the database is updated. PFGE epidemic type assignment using PFGE is required for isolates under the following criteria such as 1) no match in the MRSA typing database; 2) rare *spa* types; or 3) typing data combinations that correspond to multiple PFGE epidemic types ([Figure 1](#pone-0079149-g001){ref-type="fig"}). PFGE epidemic type designations are then reported as they have been done historically.

![A MRSA genotyping algorithm using *spa*, SCC*mec*, and PVL typing.\
PFGE epidemic types for MRSA isolates are assigned based on *spa*, SCC*mec*, and PVL data using the Alberta MRSA typing database. PFGE characterization is used for MRSA isolates that have rare or novel spa types, or have *spa*, SCC*mec*, and PVL combinations associated with more than a single PFGE epidemic type.](pone.0079149.g001){#pone-0079149-g001}

A total of 646 consecutive post-validation MRSA isolates, collected from August 2009 to November 2009, were used to evaluate the described MRSA typing algorithm and were assigned PFGE epidemic types using the Alberta MRSA typing database ([Table 2](#pone-0079149-t002){ref-type="table"}). There were 50 *spa* types identified, and two of these *spa* types- t008 (n = 361) and t044 (n = 1) -- were associated with multiple epidemic types. The majority (n = 567; 87.8%) of the isolates could be grouped into a PFGE epidemic type using *spa*, SCC*mec*, and PVL data. In particular, SCC*mec* typing data resolved the PFGE epidemic types for 359 of the 361 (99.4%) t008 isolates. PFGE epidemic type designation using PFGE was only needed for 78 isolates (12.1%; [Table 2](#pone-0079149-t002){ref-type="table"}). This group includes isolates with *spa* types corresponding to more than one PFGE epidemic type that cannot be resolved with SCC*mec* and PVL data (n = 3); isolates that have rare *spa* types or ones not previously observed in Alberta (n = 74); and isolates that have novel *spa* types not present in the online Ridom *spa* server (n = 1). One additional isolate with *spa* type t034 was not typeable using PFGE and a PFGE epidemic type was assigned based on existing data in the NML MRSA typing database.

10.1371/journal.pone.0079149.t002

###### Association of MRSA PFGE epidemic types with *spa*, SCC*mec*, and PVL types in Alberta from August 2009 to November 2009.

![](pone.0079149.t002){#pone-0079149-t002-2}

  PFGE epidemic type             Ridom *spa* type   Kreiswirth repeat succession   SCC*mec*   PVL   Total
  ----------------------------- ------------------ ------------------------------ ---------- ----- -------
  CMRSA 1 (USA600)                     t065                  A2AKBEMBKB               IV       −    2^b^
                                                                                     V\*       −    2^b^
  CMRSA 1 (USA600) Total                                                                              4
  CMRSA 2 (USA100)                     t002                  TJMBMDMGMK               II       −     81
                                       t003                   TMDMGMMK                II       −     24
                                       t014                  TMDMGMMMK                II       −      3
                                       t045                   TMDMGMK                 II       −      3
                                       t242                  TJMEMDMGMK               II       −      6
                                       t306                 TJMBMDMGMMK               II       −    3^b^
                                      t3828                  TMBMAMGMMK               II       −    1^b^
  CMRSA 2 (USA100) Total                                                                             121
  CMRSA 2 (USA800)                     t010                  TMBMDMGMK                IV       −    1^b^
                                      t1154                    TDMGMK                 IV       −      2
                                       t179                  TJMBMDMGGK               IV       −    1^b^
                                       t311                  TJMBDMGMK                IV       −      1
  CMRSA 2 (USA800) Total                                                                              5
  CMRSA 3/6                            t037                   WGKAOMQ                III       −     13
  CMRSA 3/6 Total                                                                                    13
  CMRSA 4 (USA200)                     t012                  WGKAKAOMQQ               II       −    1^b^
                                                                                      IV       −    1^b^
                                       t021                  WGKAKAOMQ                IV       −    1^b^
                                                                                              \+    1^b^
                                                                                     V\*      \+    2^b^
  CMRSA 4 (USA200) Total                                                                              6
  CMRSA 7 (USA400)                     t127                   UJFKBPE                 IV       −    1^b^
                                       t128                   UJJFKBPE                IV       −     16
                                                                                              \+     44
                                      t1786                     UJJE                  IV       −    1^b^
                                      t1787                   TJJFKBPE                IV      \+    7^b^
                                      t1788                   UJJFBPE                 IV      \+    2^b^
                                      t4671                 UJJFKBPKBPE               IV      \+    1^b^
  CMRSA 7 (USA400) Total                                                                             72
  CMRSA 8 (EMRSA-15)                   t022              TJEJNF2MNF2MOMOKR            IV       −    8^b^
                                       t032              TJJEJNF2MNF2MOMOKR           IV       −      2
                                       t852                 UJEJNCMOMOKR              IV      \+    1^b^
  CMRSA 8 (EMRSA-15) Total                                                                           11
  CMRSA 10 (USA300)                    t008                  YHGFMBQBLO               IV       −     11
                                                                                     IV\*      −    1^a^
                                                                                      IV      \+     348
                                                                                     IV\*     \+    1^a^
                                       t024                  YGFMBQBLO                IV      \+    7^b^
                                       t051                 YHFGFMBQBLO               IV      \+    1^b^
                                       t068                 YHHGFMBQBLO               IV      \+    3^b^
                                      t1610                 YHGFMBQBBLO               IV      \+    1^b^
                                      t1883                   YHGFMBQO                IV      \+    1^b^
                                      t2054                  YHGFMBOBLO               IV      \+    1^b^
                                       t211                 YHGGFMBQBLO               IV      \+    2^b^
                                      t3081                   YHGFMBPO                IV      \+    2^b^
                                      t5989                  YHQFMBQBLO               IV      \+    2^b^
                                      t6442                  YHGFMBBBLO               IV      \+    1^c^
                                       t723                    YHGBLO                 IV      \+    2^b^
                                       t818                    YHGFMB                 IV      \+    4^b^
  CMRSA 10 (USA300) Total                                                                            388
  European                             t044                   UJGBBPB                 IV      \+    1^a^
  European Total                                                                                      1
  ST398                                t034                  XKAOAOBQO               V\*      \+    1^d^
  ST398 Total                                                                                         1
  ST97                                 t521                 UJGFMBBBBPB               IV       −    1^b^
  ST97 Total                                                                                          1
  USA1000, China/Taiwan               t1894                  ZDMDMNMOB               V\*      \+    1^b^
                                       t437                   ZDMDMOB                 IV      \+    1^b^
                                      t4784                  ZDDMDMA3KB              V\*       −    1^b^
                                       t976                   ZDMDNKB                 IV      \+    1^b^
  USA1000, China/Taiwan Total                                                                         4
  USA1100, SWP/Oceania                 t019                   XKAKAOMQ                IV      \+     13
                                       t138                    XKAOMQ                 IV      \+    1^b^
  USA1100, SWP/Oceania Total                                                                         14
  USA700                               t148                 UJGFGMDMGGM               IV      \+    1^b^
                                       t791                 UJGFGMDMGMM               IV       −    1^b^
  USA700 Total                                                                                        2
  Non-assigned                        t3320                 TJEFMBBBQPB              V\*      \+    1^b^
                                       t657                   TJEFMBPB               V\*      \+    2^b^
  Non-assigned Total                                                                                  3
  Grand Total                                                                                        646

Isolates with *spa* types that correspond to more than one epidemic type and require PFGE for PFGE epidemic type assignment^a^, are rare or have not been previously observed in Alberta^b^, are novel *spa* types^c^, or could not be genotyped using PFGE^d^ are shown. Isolates marked with an \* were SCC*mec* typed with primers from Kondo *et al.* (18); all other isolates were SCC*mec* typed using primers from Oliveira *et al*. (17).

Validation of PFGE Epidemic Types Assigned using *spa*, SCC*mec*, and PVL Typing {#s3c}
--------------------------------------------------------------------------------

The accuracy of PFGE epidemic type assignment using the Alberta MRSA typing database and *spa*, SCC*mec*, and PVL data was assessed by performing PFGE on 49 isolates randomly selected from the post-validation subset of samples. Isolates were then grouped into PFGE epidemic types based on the PFGE fingerprint patterns. A comparison of *spa*-, SCC*mec*-, and PVL-based and PFGE-based epidemic type designation showed that all 49 isolates, representing 10 *spa* types and 20 PFGE fingerprint profiles, shared the same PFGE epidemic type designation regardless of typing method. Simpson's index of diversity for *spa* typing was 0.853 (95% CI, 0.810--0.896) and increased to 0.859 (95% CI, 0.813--0.905) with the addition of SCC*mec* typing alone or in conjunction with PVL characterization. These values overlapped with Simpson's index of diversity for PFGE typing (0.918; 95% CI, 0.875--0.960), suggesting the two typing algorithms had similar discriminatory power in this study.

Distribution of SCC*mec* and PVL Types in Alberta {#s3d}
-------------------------------------------------

The distribution of SCC*mec* and PVL types in the set of validation and post-validation isolates is shown in [Table 3](#pone-0079149-t003){ref-type="table"}. Most of the isolates were SCC*mec* typed using primers from Oliveira *et al*., [@pone.0079149-Oliveira2] but SCC*mec* typing for some (69 of 1915 isolates; 3.6%) required additional primers [@pone.0079149-Kondo1]. SCC*mec* type IV (n = 1129; 59.0%) was observed most frequently, followed by II (n = 644; 33.6%) then III (n = 76; 4.0%). The majority of these isolates were PVL negative (n = 1101; 57.5%) rather than PVL positive (n = 814; 42.5%). Isolates with Canadian community-associated PFGE epidemic types were predominantly SCC*mec* type IV (902 of 907; 99.4%) and PVL positive (699 of 907; 77.1%). In contrast, isolates with Canadian hospital-associated PFGE epidemic types were mostly SCC*mec* type II (608 of 797; 76.3%) and PVL negative (779 of 797; 97.7%).

10.1371/journal.pone.0079149.t003

###### Distribution of SCC*mec* and PVL types in validation and post-validation isolates.
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                                      SCC*mec*/PVL                                                                         
  --------------------------- ------ -------------- ----------- --------- ------------ ------------ ---------- ----------- ---------
  **CMRSA 1 (USA600)**          40      5 (12.5)      1 (2.5)       0      24 (60.0)     1 (2.5)     8 (20.0)       0       1 (2.5)
  **CMRSA 2 (USA100)**         610     593 (97.2)        0          0          0            0        17 (2.8)       0          0
  **CMRSA 2 (USA800)**         140         0             0          0      117 (83.6)   23 (16.4)       0           0          0
  **CMRSA 3/6**                 74         0         73 (98.6)   1 (1.4)       0            0           0           0          0
  **CMRSA 4 (USA200)**          26      9 (34.6)         0          0      11 (42.3)     2 (7.7)        0       4 (15.4)       0
  **CMRSA 5 (USA500)**          5       1 (20.0)         0          0       3 (60.0)     1 (20.0)       0           0          0
  **CMRSA 7 (USA400)**         130      5 (3.8)          0          0      48 (36.9)    77 (59.2)       0           0          0
  **CMRSA 8 (E-MRSA15)**        42         0             0          0      33 (78.6)     8 (19.0)       0        1 (2.4)       0
  **CMRSA 10 (USA300)**        637         0             0          0       38 (6.0)    599 (94.0)      0           0          0
  **European**                  17         0             0          0          0        17 (100.0)      0           0          0
  **ST88**                      8          0             0          0       4 (50.0)     4 (50.0)       0           0          0
  **ST97**                      40     24 (60.0)         0          0      12 (30.0)     1 (2.5)     3 (7.5)        0          0
  **ST398**                     1          0             0          0          0            0           0       1 (100.0)      0
  **USA700**                    25      1 (4.0)          0          0      17 (68.0)     5 (20.0)    2 (8.0)        0          0
  **USA1000, China/Taiwan**     47      1 (2.1)          0          0      25 (53.2)     9 (19.1)    4 (8.5)    8 (17.0)       0
  **USA1100, SWP/Oceania**      30         0             0          0          0        30 (100.0)      0           0          0
  **Non-assigned**              43      5 (11.6)      1 (2.3)       0      10 (23.3)    10 (23.3)    5 (11.6)   12 (27.9)      0
  **Total**                    1915    644 (33.6)    75 (3.9)    1 (0.1)   342 (17.9)   787 (41.1)   39 (2.0)   26 (1.4)    1 (0.1)

Cell percent values relative to the row total are given in brackets.

PFGE Epidemic Type Assignment using the Alberta MRSA Typing Database {#s3e}
--------------------------------------------------------------------

From January 2010 to December 2012, a total of 12620 first clinical MRSA isolates were submitted to ProvLab for molecular typing and characterized using the Alberta MRSA typing database and the described typing algorithm ([Figure 1](#pone-0079149-g001){ref-type="fig"}). The percentage of isolates requiring PFGE for PFGE epidemic type assignment from 2010 to 2012 is shown in [Table 4](#pone-0079149-t004){ref-type="table"} and decreased from 15.1% to 9.5% during this time period. SCC*mec* typing resolved the PFGE epidemic types for over 99% (n = 5923) of the t008 isolates genotyped ([Table 4](#pone-0079149-t004){ref-type="table"}).

10.1371/journal.pone.0079149.t004

###### Routine molecular testing of MRSA isolates using the Alberta MRSA typing database from 2010 to 2012.
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  Year    Total \# of MRSAisolates genotyped   \# of MRSA isolatesgenotyped by PFGE   Total \# of t008isolates   \# of t008 isolates resolvedby SCC*mec* typing
  ------ ------------------------------------ -------------------------------------- -------------------------- ------------------------------------------------
  2010                   3829                              578 (15.1%)                          1889                              1880 (99.5%)
  2011                   4306                              516 (12.0%)                          2021                              2012 (99.6%)
  2012                   4485                               427 (9.5%)                          2013                              2009 (99.8%)

Percentages of total isolates are given in brackets.

Comparing the Cost and Time Associated with PFGE and *spa*, SCC*mec*, and PVL Typing {#s3f}
------------------------------------------------------------------------------------

The total hands-on time required for PFGE typing (7.5 hours) is greater than the hands-on time required for *spa*, SCC*mec*, and PVL typing (3.5 hours) for 20 strains of MRSA. This is attributed to longer labor and data analysis times ([Table 5](#pone-0079149-t005){ref-type="table"}). In addition, turn-around times are improved for *spa*, SCC*mec*, and PVL typing (10.5 hours) compared to PFGE typing (27.5 hours) as the experiment run times are significantly reduced. Of the 12620 MRSA isolates genotyped between January 2010 and December 2012, 11099 isolates did not require PFGE typing. This reduced the required hands-on time by approximately 2220 hours. Assuming the average salary of a laboratory technologist is \$35 per hour, ProvLab saved \$77,700 in labor costs which offsets the slightly higher cost of materials associated with *spa*, SCC*mec*, and PVL typing.

10.1371/journal.pone.0079149.t005

###### Comparison of time associated with MRSA PFGE and *spa*, SCC*mec*, and PVL typing with times calculated in hours.

![](pone.0079149.t005){#pone-0079149-t005-5}

                            PFGE typing (per 20 isolates)   *spa*/SCC*mec*/PVL typing (per 20 isolates)
  ------------------------ ------------------------------- ---------------------------------------------
  Labor time                             5.0                                    3.0
  Data analysis time                     2.5                                    0.5
  Total hands-on time                    7.5                                    3.5
  Total turn-around time                27.5                                   10.5

Discussion {#s4}
==========

Although PFGE is a powerful MRSA genotyping technique, it has many limitations. As the number of MRSA isolates submitted to ProvLab increased, PFGE characterization became much less viable. In this study, we describe the transition from using PFGE to assign MRSA PFGE epidemic types, to using *spa*, SCC*mec*, and PVL typing. With the new Alberta MRSA typing database, most (n = 11666; 87.9%) of the 13266 isolates genotyped after the validation of the typing algorithm were grouped into PFGE epidemic types using *spa*, SCC*mec*, and PVL data. A total of 1600 isolates (12.1%) still needed PFGE for PFGE epidemic type assignment. The number of first clinical MRSA isolates requiring PFGE for PFGE epidemic type assignment steadily declined from 15.1% in 2010 to 9.5% in 2012, further reducing the time and cost associated with MRSA genotyping at ProvLab. As the new Alberta MRSA typing database becomes more populated, isolates with rare or novel *spa* types will become less frequent leading to additional reductions in the PFGE workload.

In this study, isolates with community-associated epidemic types were predominantly SCC*mec* type IV and PVL positive, while those with hospital-associated epidemic types were mostly SCC*mec* type II and PVL negative. These findings are consistent with global trends (as reviewed in [@pone.0079149-David1]). An isolate with *spa* type t034 was observed in this study and it could not be genotyped using PFGE or be assigned to a PFGE epidemic type using the new Alberta MRSA typing database. This isolate was grouped into the PFGE epidemic type ST398 based on past designations made by NML, is known to be resistant to *Sma*I digestion, and is associated with livestock [@pone.0079149-Golding2], [@pone.0079149-Smith1]. Characterization of similar isolates in the future will need to be done using only *spa*, SCC*mec*, and PVL data.

PFGE epidemic type designations were consistent regardless of typing method for selected isolates, a result seen in other studies [@pone.0079149-Golding1], [@pone.0079149-Hallin1], [@pone.0079149-Faria1], [@pone.0079149-Tang1], allowing for an easy transition between the two typing methodologies. Although the cost of laboratory supplies for PFGE typing at ProvLab are lower, the cost differential is offset by the significant time and subsequent labor cost savings gained from using *spa*, SCC*mec*, and PVL typing. The turn-around and hands-on times required for *spa*, SCC*mec*, and PVL typing is reduced by more than half compared to PFGE. This is due in part to the computer automation of *spa* typing analyses. At ProvLab, the *spa* typing module accompanying the BioNumerics software is used to automatically analyze *spa* data and assign PFGE epidemic types. In contrast, PFGE data must be manually interpreted and PFGE epidemic types are assigned after careful comparison with representative epidemic strains. As a result, analysis of PFGE data is much more subjective and susceptible to interpretation errors.

SCC*mec* typing was needed to resolve MRSA isolates associated with more than one PFGE epidemic type and was particularly useful for differentiating t008 isolates, as well as PFGE epidemic types CMRSA 2 (USA100) and CMRSA 2 (USA800) which otherwise could not be resolved using PFGE. PVL characterization was not able to differentiate isolates associated with multiple PFGE epidemic types, although it could be used as a general indicator of PFGE epidemic type for select *spa* types (t044). Although SCC*mec* and PVL results are also manually interpreted, these assays produce data that is much faster to analyze.

To conclude, we created a new MRSA typing database in Alberta and validated and used an algorithm for genotyping MRSA using *spa*, SCC*mec*, and PVL typing. The shift away from PFGE typing provides significant time and cost savings, and enables high throughput processing while maintaining historical PFGE epidemic type assignments and reporting. Although PFGE typing is still required at ProvLab, its role is limited and will be further reduced as the Alberta MRSA typing database becomes more populated. A limitation of this study is that it was done at a reference provincial public health laboratory; thus the findings may not be applicable to all settings and other typing methods may still have an important role to play. Additionally, the time and cost savings will vary significantly between different laboratories because of differences in equipment, salary, cost of materials, and technical expertise.
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